ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Remicade (Infliximab) and Biosimilar Market Research Report 2023
Published Date: June 2023
|
Report Code: QYRE-Auto-5O14665
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Remicade Infliximab and Biosimilar Market Research Report 2023
BUY CHAPTERS

Global Remicade (Infliximab) and Biosimilar Market Research Report 2023

Code: QYRE-Auto-5O14665
Report
June 2023
Pages:69
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Key
Amgen Inc
Organon
J & J
Pfizer Inc

Remicade (Infliximab) and Biosimilar Market Size

According to QYResearch’s new survey, global Remicade (Infliximab) and Biosimilar market is projected to reach US$ 3855 million in 2029, increasing from US$ 2550 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029.

Remicade (Infliximab) and Biosimilar Market

Remicade (Infliximab) and Biosimilar Market

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Remicade (Infliximab) and Biosimilar market research.
Key manufacturers engaged in the Remicade (Infliximab) and Biosimilar industry include J & J, Pfizer, Organon and Amgen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Remicade (Infliximab) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Remicade (Infliximab) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Remicade (Infliximab) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Remicade (Infliximab) and Biosimilar Market Report

Report Metric Details
Report Name Remicade (Infliximab) and Biosimilar Market
Accounted market size in 2022 US$ 2550 million
Forecasted market size in 2029 US$ 3855 million
CAGR 5.6%
Base Year 2022
Forecasted years 2023 - 2029
Segment by Type
  • Brand
  • Biosimilar
Segment by Application
  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company J & J, Pfizer, Organon, Amgen
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

How fast is Remicade (Infliximab) and Biosimilar Market market growing?

Ans: The Remicade (Infliximab) and Biosimilar Market market witnessing a CAGR of 5.6% during the forecast period 2023-2029.

What is the Remicade (Infliximab) and Biosimilar Market market size in 2029?

Ans: According to QYResearch’s new survey, global Remicade (Infliximab) and Biosimilar market is projected to reach US$ 3855 million in 2029, increasing from US$ 2550 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029.

1 Remicade (Infliximab) and Biosimilar Market Overview
1.1 Product Overview and Scope of Remicade (Infliximab) and Biosimilar
1.2 Remicade (Infliximab) and Biosimilar Segment by Type
1.2.1 Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Remicade (Infliximab) and Biosimilar Segment by Application
1.3.1 Global Remicade (Infliximab) and Biosimilar Market Value by Application: (2023-2029)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn’s Disease
1.3.5 Other
1.4 Global Remicade (Infliximab) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Remicade (Infliximab) and Biosimilar Revenue 2018-2029
1.4.2 Global Remicade (Infliximab) and Biosimilar Sales 2018-2029
1.4.3 Global Remicade (Infliximab) and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Remicade (Infliximab) and Biosimilar Market Competition by Manufacturers
2.1 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Remicade (Infliximab) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Remicade (Infliximab) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Product Type & Application
2.7 Remicade (Infliximab) and Biosimilar Market Competitive Situation and Trends
2.7.1 Remicade (Infliximab) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Remicade (Infliximab) and Biosimilar Players Market Share by Revenue
2.7.3 Global Remicade (Infliximab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Remicade (Infliximab) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Remicade (Infliximab) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Remicade (Infliximab) and Biosimilar Global Remicade (Infliximab) and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2024-2029
3.3 Global Remicade (Infliximab) and Biosimilar Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2024-2029
3.4 North America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Remicade (Infliximab) and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Remicade (Infliximab) and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Remicade (Infliximab) and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Remicade (Infliximab) and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 J & J
6.1.1 J & J Corporation Information
6.1.2 J & J Description and Business Overview
6.1.3 J & J Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 J & J Remicade (Infliximab) and Biosimilar Product Portfolio
6.1.5 J & J Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Organon
6.3.1 Organon Corporation Information
6.3.2 Organon Description and Business Overview
6.3.3 Organon Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Organon Remicade (Infliximab) and Biosimilar Product Portfolio
6.3.5 Organon Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Remicade (Infliximab) and Biosimilar Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Remicade (Infliximab) and Biosimilar Industry Chain Analysis
7.2 Remicade (Infliximab) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Remicade (Infliximab) and Biosimilar Production Mode & Process
7.4 Remicade (Infliximab) and Biosimilar Sales and Marketing
7.4.1 Remicade (Infliximab) and Biosimilar Sales Channels
7.4.2 Remicade (Infliximab) and Biosimilar Distributors
7.5 Remicade (Infliximab) and Biosimilar Customers
8 Remicade (Infliximab) and Biosimilar Market Dynamics
8.1 Remicade (Infliximab) and Biosimilar Industry Trends
8.2 Remicade (Infliximab) and Biosimilar Market Drivers
8.3 Remicade (Infliximab) and Biosimilar Market Challenges
8.4 Remicade (Infliximab) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Key
Amgen Inc
Organon
J & J
Pfizer Inc
List of Tables
    Table 1. Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Remicade (Infliximab) and Biosimilar Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Remicade (Infliximab) and Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)
    Table 5. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Remicade (Infliximab) and Biosimilar Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Remicade (Infliximab) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Remicade (Infliximab) and Biosimilar, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Product Type & Application
    Table 12. Global Key Manufacturers of Remicade (Infliximab) and Biosimilar, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Remicade (Infliximab) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) and Biosimilar as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Remicade (Infliximab) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Remicade (Infliximab) and Biosimilar Sales by Region (2018-2023) & (K Units)
    Table 18. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2018-2023)
    Table 19. Global Remicade (Infliximab) and Biosimilar Sales by Region (2024-2029) & (K Units)
    Table 20. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2024-2029)
    Table 21. Global Remicade (Infliximab) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2018-2023)
    Table 23. Global Remicade (Infliximab) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2024-2029)
    Table 25. North America Remicade (Infliximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Remicade (Infliximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 27. North America Remicade (Infliximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 28. North America Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Remicade (Infliximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Remicade (Infliximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Remicade (Infliximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 32. Europe Remicade (Infliximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 33. Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Region (2018-2023) & (K Units)
    Table 37. Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Region (2024-2029) & (K Units)
    Table 38. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Remicade (Infliximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Remicade (Infliximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 42. Latin America Remicade (Infliximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 43. Latin America Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Remicade (Infliximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Remicade (Infliximab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Remicade (Infliximab) and Biosimilar Sales by Country (2018-2023) & (K Units)
    Table 47. Middle East & Africa Remicade (Infliximab) and Biosimilar Sales by Country (2024-2029) & (K Units)
    Table 48. Middle East & Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Type (2018-2023)
    Table 51. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Type (2024-2029)
    Table 52. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2018-2023)
    Table 53. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2024-2029)
    Table 54. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2018-2023)
    Table 57. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2024-2029)
    Table 58. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Type (2018-2023)
    Table 59. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Type (2024-2029)
    Table 60. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Application (2018-2023)
    Table 61. Global Remicade (Infliximab) and Biosimilar Sales (K Units) by Application (2024-2029)
    Table 62. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2018-2023)
    Table 63. Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2024-2029)
    Table 64. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Remicade (Infliximab) and Biosimilar Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2018-2023)
    Table 67. Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2024-2029)
    Table 68. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Application (2018-2023)
    Table 69. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Application (2024-2029)
    Table 70. J & J Corporation Information
    Table 71. J & J Description and Business Overview
    Table 72. J & J Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 73. J & J Remicade (Infliximab) and Biosimilar Product
    Table 74. J & J Recent Developments/Updates
    Table 75. Pfizer Corporation Information
    Table 76. Pfizer Description and Business Overview
    Table 77. Pfizer Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 78. Pfizer Remicade (Infliximab) and Biosimilar Product
    Table 79. Pfizer Recent Developments/Updates
    Table 80. Organon Corporation Information
    Table 81. Organon Description and Business Overview
    Table 82. Organon Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 83. Organon Remicade (Infliximab) and Biosimilar Product
    Table 84. Organon Recent Developments/Updates
    Table 85. Amgen Corporation Information
    Table 86. Amgen Description and Business Overview
    Table 87. Amgen Remicade (Infliximab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 88. Amgen Remicade (Infliximab) and Biosimilar Product
    Table 89. Amgen Recent Developments/Updates
    Table 90. Key Raw Materials Lists
    Table 91. Raw Materials Key Suppliers Lists
    Table 92. Remicade (Infliximab) and Biosimilar Distributors List
    Table 93. Remicade (Infliximab) and Biosimilar Customers List
    Table 94. Remicade (Infliximab) and Biosimilar Market Trends
    Table 95. Remicade (Infliximab) and Biosimilar Market Drivers
    Table 96. Remicade (Infliximab) and Biosimilar Market Challenges
    Table 97. Remicade (Infliximab) and Biosimilar Market Restraints
    Table 98. Research Programs/Design for This Report
    Table 99. Key Data Information from Secondary Sources
    Table 100. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Remicade (Infliximab) and Biosimilar
    Figure 2. Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Remicade (Infliximab) and Biosimilar Market Share by Type in 2022 & 2029
    Figure 4. Brand Product Picture
    Figure 5. Biosimilar Product Picture
    Figure 6. Global Remicade (Infliximab) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 7. Global Remicade (Infliximab) and Biosimilar Market Share by Application in 2022 & 2029
    Figure 8. Ankylosing Spondylitis
    Figure 9. Rheumatoid Arthritis
    Figure 10. Crohn’s Disease
    Figure 11. Other
    Figure 12. Global Remicade (Infliximab) and Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 13. Global Remicade (Infliximab) and Biosimilar Market Size (2018-2029) & (US$ Million)
    Figure 14. Global Remicade (Infliximab) and Biosimilar Sales (2018-2029) & (K Units)
    Figure 15. Global Remicade (Infliximab) and Biosimilar Average Price (US$/Unit) & (2018-2029)
    Figure 16. Remicade (Infliximab) and Biosimilar Report Years Considered
    Figure 17. Remicade (Infliximab) and Biosimilar Sales Share by Manufacturers in 2022
    Figure 18. Global Remicade (Infliximab) and Biosimilar Revenue Share by Manufacturers in 2022
    Figure 19. The Global 5 and 10 Largest Remicade (Infliximab) and Biosimilar Players: Market Share by Revenue in 2022
    Figure 20. Remicade (Infliximab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 21. Global Remicade (Infliximab) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 22. North America Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 23. North America Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 24. United States Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 25. Canada Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 26. Europe Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 27. Europe Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 28. Germany Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. France Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 30. U.K. Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 31. Italy Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 32. Russia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. Asia Pacific Remicade (Infliximab) and Biosimilar Sales Market Share by Region (2018-2029)
    Figure 34. Asia Pacific Remicade (Infliximab) and Biosimilar Revenue Market Share by Region (2018-2029)
    Figure 35. China Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Japan Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 37. South Korea Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 38. India Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 39. Australia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. China Taiwan Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. Southeast Asia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. Latin America Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 43. Latin America Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 44. Mexico Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Brazil Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 46. Argentina Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 47. Middle East & Africa Remicade (Infliximab) and Biosimilar Sales Market Share by Country (2018-2029)
    Figure 48. Middle East & Africa Remicade (Infliximab) and Biosimilar Revenue Market Share by Country (2018-2029)
    Figure 49. Turkey Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 50. Saudi Arabia Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 51. UAE Remicade (Infliximab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 52. Global Sales Market Share of Remicade (Infliximab) and Biosimilar by Type (2018-2029)
    Figure 53. Global Revenue Market Share of Remicade (Infliximab) and Biosimilar by Type (2018-2029)
    Figure 54. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Type (2018-2029)
    Figure 55. Global Sales Market Share of Remicade (Infliximab) and Biosimilar by Application (2018-2029)
    Figure 56. Global Revenue Market Share of Remicade (Infliximab) and Biosimilar by Application (2018-2029)
    Figure 57. Global Remicade (Infliximab) and Biosimilar Price (US$/Unit) by Application (2018-2029)
    Figure 58. Remicade (Infliximab) and Biosimilar Value Chain
    Figure 59. Remicade (Infliximab) and Biosimilar Production Process
    Figure 60. Channels of Distribution (Direct Vs Distribution)
    Figure 61. Distributors Profiles
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions